Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4598698

CCOc1cccc(C(Nc2cccc(C(N)=O)c2)C(=O)NCc2cc(NC(C)=O)ccc2S(=O)(=O)CC)c1.O=C(O)C(F)(F)F

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
F7 P08709 7/20 0.50
F3 P13726 5/20 0.50
F2 P00734 5/20 0.50
F10 P00742 5/20 0.50
F11 P03951 3/20 0.50
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
DDR1 Q08345 5/20 0.39
POLB P06746 1/20 0.39
PRSS1 P07477 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
LMNA P02545 1/20 0.37
EPHX2 P34913 1/20 0.36
NR1H4 Q96RI1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8251269 0.95 F7 (0.54) F7F3F2F10F11
Trifluoroacetic Acid SCHEMBL5006709 0.89 F7 (0.50) F7F3F2F10F11
SCHEMBL4598702 0.89 F7 (0.52) F7F3F2F10F11
Trifluoroacetic Acid SCHEMBL5003110 0.88 F7 (0.49) F7F3F2F10F11
Trifluoroacetic Acid SCHEMBL5003791 0.88 F7 (0.49) F7F3F2F10F11
Trifluoroacetic Acid SCHEMBL5003515 0.88 F7 (0.49) F7F3F2F10F11
Trifluoroacetic Acid SCHEMBL5003012 0.86 F7 (0.49) F7F3F2F10F11
Trifluoroacetic Acid SCHEMBL2854587 0.85 F7 (0.70) F7F3F2F10F11
SCHEMBL14009133 0.84 F7 (0.54) F7F3F2F10F11
SCHEMBL14009141 0.83 F7 (0.53) F7F3F2F10F11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456195-B2 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-25 US disclosed
EP-1910298-A2 PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS Brystol-Myers Squibb Company (US) 2008-04-16 EP disclosed
WO-2007002313-A2 PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 WO disclosed
US-20070003539-A1 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070003539-A1 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants F12, F11, F7 F7 3/4885F3 10/4885F2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.